Sulpiride (Standard)

Sulpiride (Standard) is the analytical standard of Sulpiride. This product is intended for research and analytical applications. Sulpiride is an orally active dopamine D2/D3 receptor antagonist. Sulpiride is an atypical antipsychotic agent of the benzamide family. Sulpiride can be used in research into anxiety, depression and breast cancer[1][2][3].

Product Specifications

CAS Number

[15676-16-1]

UNSPSC

12352005

Hazard Statement

H302, H312, H315, H319, H332, H335, H361

Target

Dopamine Receptor; Reference Standards

Type

Reference Standards

Related Pathways

GPCR/G Protein; Neuronal Signaling; Others

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/sulpiride-standard.html

Purity

99.94

Smiles

O=C(NCC1N(CC)CCC1)C2=CC(S(=O)(N)=O)=CC=C2OC

Molecular Formula

C15H23N3O4S

Molecular Weight

341.43

Precautions

H302, H312, H315, H319, H332, H335, H361

References & Citations

[1]Rüther, E et al. Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial. Pharmacopsychiatry vol. 32,4 (1999) : 127-35. |[2]Jaworski, J N et al. Effect of dopamine D2/D3 receptor antagonist sulpiride on amphetamine-induced changes in striatal extracellular dopamine. European journal of pharmacology vol. 418,3 (2001) : 201-6. |[3]Zarrindast, Mohammad-Reza et al. Synergistic effect between quinpirole and L-NAME as well as sulpiride and L-arginine on the modulation of anxiety and memory processes in the 6-OHDA mouse model of Parkinson's disease: An isobologram analysis. Neurobiology of learning and memory vol. 186 (2021) : 107538. |[4]Li, Jian et al. Dopamine D2 receptor antagonist sulpiride enhances dexamethasone responses in the treatment of drug-resistant and metastatic breast cancer. Acta pharmacologica Sinica vol. 38,9 (2017) : 1282-1296.